We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $931M
1-Year Est. Return 41.63%
This Fund
S&P 500
This Quarter Est. Return
+1.53%
1 Year Est. Return
+41.63%
3 Year Est. Return
+181.18%
5 Year Est. Return
+113.34%
10 Year Est. Return
+1,823.73%
AUM
$4.93B
AUM Growth
-$733M
Cap. Flow
-$52.9M
Cap. Flow %
-1.07%
Top 10 Hldgs %
45.48%
Holding
165
New
19
Increased
18
Reduced
16
Closed
21

Top Buys

Rank Stock Value
1
OTLY
Oatly Group
OTLY
+$37.3M
2
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$32.5M
3
TRML
Tourmaline Bio
TRML
+$31.6M
4
SAGE
Sage Therapeutics
SAGE
+$24.7M
5
VERV
Verve Therapeutics
VERV
+$20.8M

Top Sells

Rank Stock Value
1
BNTX icon
BioNTech
BNTX
+$98.3M
2
INTC icon
Intel
INTC
+$47M
3
CCXI
ChemoCentryx, Inc.
CCXI
+$38.4M
4
AVGO icon
Broadcom
AVGO
+$34.8M
5
BEKE icon
KE Holdings
BEKE
+$34.2M

Sector Composition

Rank Sector Weight
1 Healthcare 75.69%
2 Consumer Discretionary 10.87%
3 Miscellaneous 10.83%
4 Consumer Staples 0.74%
5 Industrials 0.47%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ADAG
76
Adagene
ADAG
$228M
$13.6M 0.28%
1,000,000
+200,000
+25% +$2.78M
YMAB
77
DELISTED
Y-mAbs Therapeutics
YMAB
$13.5M 0.27%
400,000
– –
AUPH icon
78
Aurinia Pharmaceuticals
AUPH
$2.14B
$13M 0.26%
1,000,000
– –
KURA icon
79
Kura Oncology
KURA
$1.03B
$12.5M 0.25%
600,000
– –
TCRR
80
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
$12.3M 0.25%
750,000
– –
AGL icon
81
Agilon Health
AGL
$1.55B
$12.2M 0.25%
+12,000
New +$10.5M
KYMR icon
82
Kymera Therapeutics
KYMR
$9.53B
$12.1M 0.25%
250,000
– –
LYEL icon
83
Lyell Immunopharma
LYEL
$293M
$11.4M 0.23%
+35,000
New +$11.5M
DYN icon
84
Dyne Therapeutics
DYN
$3.46B
$11M 0.22%
525,000
– –
CYCN
85
DELISTED
Cyclerion Therapeutics
CYCN
$10.8M 0.22%
138,956
+48,077
+53% +$3.01M
ADVM
86
DELISTED
Adverum Biotechnologies
ADVM
$10.5M 0.21%
300,000
+60,000
+25% +$3.23M
CRIS icon
87
Curis
CRIS
$2.72M
$10.5M 0.21%
3,250
-1,262
-28% -$5.7M
VOR icon
88
Vor Biopharma
VOR
$1.37B
$10.3M 0.21%
27,500
– –
CYTK icon
89
Cytokinetics
CYTK
$10.1B
$9.89M 0.2%
+500,000
New +$11.7M
OVID icon
90
Ovid Therapeutics
OVID
$535M
$9.78M 0.2%
2,500,000
– –
SYRS
91
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$9.27M 0.19%
170,000
+67,500
+66% +$4M
BPMC
92
DELISTED
Blueprint Medicines
BPMC
$8.8M 0.18%
+100,000
New +$9.16M
YI
93
111 Inc
YI
$31.6M
$8.78M 0.18%
96,635
– –
TIL icon
94
Instil Bio
TIL
$50.1M
$8.69M 0.18%
22,500
– –
IMUX icon
95
Immunic
IMUX
$153M
$8.58M 0.17%
70,000
– –
STOK icon
96
Stoke Therapeutics
STOK
$1.87B
$8.41M 0.17%
250,000
– –
APLT
97
DELISTED
Applied Therapeutics
APLT
$8.31M 0.17%
400,000
– –
SLDB icon
98
Solid Biosciences
SLDB
$933M
$8.23M 0.17%
150,000
– –
DSGN icon
99
Design Therapeutics
DSGN
$846M
$7.96M 0.16%
400,000
– –
ACIU icon
100
AC Immune
ACIU
$274M
$7.93M 0.16%
1,000,000
– –
2 3
4
5 6

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $931M AUM 47.97% 1-Year Est. Return
ACM
Ashe Capital Management Englewood Cliffs, New Jersey $931M AUM 4.95% 1-Year Est. Return
SAM
Sycomore Asset Management Paris, France $932M AUM 51.25% 1-Year Est. Return
NS
Night Squared New York $930M AUM 56.46% 1-Year Est. Return
PA
Planning Alternatives Birmingham, Michigan $933M AUM 28.32% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $933M AUM 56.2% 1-Year Est. Return
CICI
Capital Investment Counsel Inc Raleigh, North Carolina $929M AUM 53.07% 1-Year Est. Return
CAM
Claret Asset Management Montreal, Quebec, Canada $928M AUM 25.4% 1-Year Est. Return

Artal Group's Q2 2021 Portfolio in Review

As of Q2 2021, Artal Group held 165 positions worth $4.93B, down 13% from $5.66B the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Artal Group's Q2 2021 filing shows 19 new, 18 increased, 16 reduced and 21 closed positions. Its largest new stake was Oatly Group: 75,000 shares worth $36.7M. The largest sale was BioNTech, an estimated $98.3M.

By sector, the portfolio is most concentrated in Healthcare at 76% of assets, up from 70% a quarter earlier, followed by Consumer Discretionary and Miscellaneous.

  • Artal Group's largest Q2 2021 buy was Oatly Group: 75,000 shares worth $36.7M.
  • Artal Group added most to Sage Therapeutics in Q2 2021, an estimated $24.7M increase.
  • Artal Group's biggest Q2 2021 reduction was TG Therapeutics, cutting an estimated $27.5M.
  • Artal Group fully exited BioNTech in Q2 2021, selling an estimated $98.3M.
  • Artal Group's ten largest holdings make up 45% of its $4.93B portfolio in Q2 2021.
  • Artal Group opened 19 new positions and closed 21 in Q2 2021.
  • Artal Group's portfolio value fell 13% quarter-over-quarter to $4.93B.

Based on Artal Group's 13F filing for Q2 2021, filed 13 Aug 2021.